Sunesis Pharmaceuticals (SNSS) Tops Q1 EPS by 3c

Sunesis Pharmaceuticals (NASDAQ: SNSS) reported Q1 EPS of ($0.13), $0.03 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $854 thousand versus the consensus estimate of $980 thousand.

For earnings history and earnings-related data on Sunesis Pharmaceuticals (SNSS) click here.

You May Also Be Interested In

• Rivian reports record Q3 deliveries, beats estimates, shares rise
• Niu Technologies Q3 2026 unit sales rise 15% year over year
• Citi upgrades Harley-Davidson to Buy with $33 price target